|
Alkem Laboratories Limited (ALKEM.NS) Avaliação DCF
IN | Healthcare | Drug Manufacturers - Specialty & Generic | NSE
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Alkem Laboratories Limited (ALKEM.NS) Bundle
Projetado para precisão, nossa calculadora DCF (Alkemns) capacita a avaliação da Alkem Laboratories Limited usando dados financeiros do mundo real, juntamente com a completa flexibilidade para modificar todos os parâmetros-chave para projeções aprimoradas.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 81,919.6 | 87,284.0 | 105,120.3 | 115,992.6 | 126,675.8 | 141,413.3 | 157,865.4 | 176,231.5 | 196,734.3 | 219,622.4 |
| Revenue Growth, % | 0 | 6.55 | 20.43 | 10.34 | 9.21 | 11.63 | 11.63 | 11.63 | 11.63 | 11.63 |
| EBITDA | 15,776.1 | 21,756.0 | 21,906.6 | 17,225.5 | 24,195.1 | 27,992.4 | 31,249.0 | 34,884.5 | 38,943.0 | 43,473.7 |
| EBITDA, % | 19.26 | 24.93 | 20.84 | 14.85 | 19.1 | 19.79 | 19.79 | 19.79 | 19.79 | 19.79 |
| Depreciation | 2,527.6 | 2,745.8 | 3,039.6 | 3,104.2 | 2,993.0 | 4,005.3 | 4,471.3 | 4,991.5 | 5,572.2 | 6,220.5 |
| Depreciation, % | 3.09 | 3.15 | 2.89 | 2.68 | 2.36 | 2.83 | 2.83 | 2.83 | 2.83 | 2.83 |
| EBIT | 13,248.5 | 19,010.2 | 18,867.0 | 14,121.3 | 21,202.1 | 23,987.1 | 26,777.7 | 29,893.0 | 33,370.8 | 37,253.2 |
| EBIT, % | 16.17 | 21.78 | 17.95 | 12.17 | 16.74 | 16.96 | 16.96 | 16.96 | 16.96 | 16.96 |
| Total Cash | 4,602.9 | 17,537.0 | 13,130.3 | 31,238.5 | 42,697.2 | 27,954.2 | 31,206.4 | 34,837.0 | 38,890.0 | 43,414.4 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 19,109.5 | 19,213.3 | 18,879.7 | 21,442.4 | 22,854.6 | 28,233.9 | 31,518.6 | 35,185.5 | 39,279.0 | 43,848.7 |
| Account Receivables, % | 23.33 | 22.01 | 17.96 | 18.49 | 18.04 | 19.97 | 19.97 | 19.97 | 19.97 | 19.97 |
| Inventories | 18,188.2 | 23,124.4 | 30,055.3 | 26,075.3 | 26,611.8 | 34,158.4 | 38,132.4 | 42,568.7 | 47,521.2 | 53,049.8 |
| Inventories, % | 22.2 | 26.49 | 28.59 | 22.48 | 21.01 | 24.16 | 24.16 | 24.16 | 24.16 | 24.16 |
| Accounts Payable | 9,540.5 | 10,694.1 | 11,733.8 | 11,650.3 | 17,481.2 | 16,659.7 | 18,597.9 | 20,761.6 | 23,177.1 | 25,873.5 |
| Accounts Payable, % | 11.65 | 12.25 | 11.16 | 10.04 | 13.8 | 11.78 | 11.78 | 11.78 | 11.78 | 11.78 |
| Capital Expenditure | -3,630.9 | -1,949.1 | -3,388.8 | -2,329.1 | -2,592.9 | -3,943.7 | -4,402.5 | -4,914.7 | -5,486.5 | -6,124.8 |
| Capital Expenditure, % | -4.43 | -2.23 | -3.22 | -2.01 | -2.05 | -2.79 | -2.79 | -2.79 | -2.79 | -2.79 |
| Tax Rate, % | 11.24 | 11.24 | 11.24 | 11.24 | 11.24 | 11.24 | 11.24 | 11.24 | 11.24 | 11.24 |
| EBITAT | 11,852.8 | 16,357.2 | 16,834.7 | 10,651.5 | 18,819.4 | 20,577.4 | 22,971.4 | 25,643.9 | 28,627.4 | 31,957.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -17,007.7 | 13,267.5 | 10,927.9 | 12,760.4 | 23,101.7 | 6,891.7 | 17,719.7 | 19,781.2 | 22,082.5 | 24,651.6 |
| WACC, % | 6.68 | 6.67 | 6.68 | 6.65 | 6.68 | 6.67 | 6.67 | 6.67 | 6.67 | 6.67 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 73,233.2 | |||||||||
| Long Term Growth Rate, % | 3.50 | |||||||||
| Free cash flow (T + 1) | 25,514 | |||||||||
| Terminal Value | 804,408 | |||||||||
| Present Terminal Value | 582,409 | |||||||||
| Enterprise Value | 655,642 | |||||||||
| Net Debt | 9,633 | |||||||||
| Equity Value | 646,009 | |||||||||
| Diluted Shares Outstanding, MM | 120 | |||||||||
| Equity Value Per Share | 5,402.99 |
What You Will Receive
- Flexible Forecast Inputs: Seamlessly adjust key assumptions (growth %, margins, WACC) to explore various scenarios.
- Comprehensive Market Data: Alkem Laboratories Limited's (ALKEMNS) financial figures provided upfront to facilitate your analysis.
- Automated DCF Calculations: The template computes Net Present Value (NPV) and intrinsic value for you automatically.
- Professional and Tailored: A refined Excel model that customizes to your valuation requirements.
- Designed for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.
Key Features
- Customizable Forecast Inputs: Adjust essential factors such as revenue growth, EBITDA percentage, and capital expenditures with ease.
- Instant DCF Valuation: Quickly computes intrinsic value, NPV, and additional financial metrics.
- Industry-Leading Precision: Based on Alkem Laboratories Limited's (ALKEMNS) actual financial data for accurate valuation results.
- Effortless Scenario Analysis: Evaluate various assumptions and analyze results without complications.
- Efficiency Booster: Avoid the hassle of constructing complex valuation models from the ground up.
How It Functions
- Step 1: Download the pre-built Excel template containing Alkem Laboratories Limited (ALKEMNS) data.
- Step 2: Navigate through the populated sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see the updated results, including the intrinsic value of Alkem Laboratories Limited (ALKEMNS).
- Step 5: Utilize the outputs to make well-informed investment decisions or create reports.
Why Choose the Alkem Laboratories Limited (ALKEMNS) Calculator?
- Time Efficient: Skip the hassle of building a DCF model from the ground up – it’s ready for immediate use.
- Enhanced Accuracy: Dependable financial data and formulas minimize valuation errors.
- Completely Customizable: Adjust the model to align with your specific assumptions and forecasts.
- User-Friendly: Intuitive charts and outputs simplify data analysis.
- Endorsed by Professionals: Crafted for industry experts who prioritize precision and functionality.
Who Can Benefit from This Product?
- Finance Students: Master valuation techniques and apply them with real-world data.
- Researchers: Utilize industry models in your academic studies or research projects.
- Investors: Validate your hypotheses and assess valuation scenarios for Alkem Laboratories Limited (ALKEMNS).
- Analysts: Enhance your efficiency with a ready-to-use, customizable DCF model.
- Small Business Owners: Discover how large public companies like Alkem Laboratories Limited (ALKEMNS) are evaluated.
Contents of the Template
- Comprehensive DCF Model: Fully editable template featuring intricate valuation calculations.
- Real-World Data: Alkem Laboratories Limited’s (ALKEMNS) historical and projected financial information preloaded for in-depth analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Interactive charts and tables providing clear and actionable results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.